Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminoethyl Nitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoethyl Nitrate SCHEMBL10944529 | 0.98 | CA5A (0.38) | CA5ACA5BALDH1A1CA12CA1 | |
| Aminoethyl Nitrate SCHEMBL457055 | 0.92 | — | — | |
| Aminoethyl Nitrate SCHEMBL7846288 | 0.90 | — | — | |
| Nitric Acid SCHEMBL220687 | 0.86 | CA12 (0.40) | CA5ACA5BALDH1A1CA12CA1 | |
| Nitric Acid SCHEMBL2564368 | 0.84 | CA12 (0.42) | CA5ACA5BALDH1A1CA12CA1 | |
| Ethylenediamine SCHEMBL721753 | 0.81 | CA5A (0.61) | CA5ACA5BALDH1A1 | |
| Ethylenediamine SCHEMBL6232364 | 0.81 | CA5A (0.61) | CA5ACA5BALDH1A1 | |
| Ethylenediamine SCHEMBL2733332 | 0.81 | CA5A (0.61) | CA5ACA5BALDH1A1 | |
| Ethylenediamine SCHEMBL723589 | 0.81 | — | — | |
| Ethylenediamine SCHEMBL28858090 | 0.81 | CA5A (0.61) | CA5ACA5BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111592436-A | Low-vulnerability propellant and preparation method thereof | 湖北三江航天江河化工科技有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| CN-108864386-B | Modulus regulator, preparation method and application thereof | 湖北航天化学技术研究所 | 2020-12-18 | — | — | CN | disclosed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111592436-A | Low-vulnerability propellant and preparation method thereof | 湖北三江航天江河化工科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-106316729-B | Azide polyether propellant with wide adaptability | 湖北航天化学技术研究所 | 2020-03-24 | — | — | CN | disclosed |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-5272164-A | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223508-A | Hypotensive agents, vasodilators | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0540544-A1 | BENZOIC ACID SUBSTITUTED DERIVATIVES HAVING CARDIOVASCULAR ACTIVITY. | ITALFARMACO SPA (IT) | 1993-05-12 | — | — | EP | disclosed |
| US-5166347-A | Hypotensive agents, cardiovascular disorders, antiischemic agents and anticoagulants | KIRIN BEER KABUSHIKI KAISHA (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0506434-A1 | Thiazolidinone and oxazolidinone derivatives, their preparation and their use as vasodilators | Sankyo Company Limited (JP) | 1992-09-30 | — | — | EP | disclosed |
| WO-1992001668-A1 | BENZOIC ACID SUBSTITUTED DERIVATIVES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1992-02-06 | — | — | WO | disclosed |
| EP-0388528-A2 | Carboximidamide derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4886822-A | SIDE EFFECT REDUCTION | KOWA COMPANY, LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0286979-A1 | Substituted anilide derivatives | KOWA COMPANY, LTD. (JP) | 1988-10-19 | — | — | EP | disclosed |
| US-4612313-A | Pharmaceutical phenylacetonitrile derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1986-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | CNR2, CNR1, CHRNB3 | CA5A 2230/4885CA5B 2102/4885ALDH1A1 1850/4885 |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | CA5A 1675/4885CA5B 2123/4885ALDH1A1 580/4885 |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | CNR2, CNR1, CHRNB3 | CA5A 2230/4885CA5B 2102/4885ALDH1A1 1850/4885 |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | CA5A 946/4885CA5B 1451/4885ALDH1A1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.